ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced that data ...

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with ...

Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive ...

SBP launches a new digital platform allowing individuals and corporates to invest in government securities online.

In this Q&A, Beowolff Capital CEO Andrew Wolff explains why he believes the future of the art market lies in transparency, data and A.I.-powered collaboration. He outlines how integrating ...

In a pivotal PPMS study (FENtrepid), fenebrutinib slowed disability progression at least as effectively as OCREVUS, the only approved therapy in PPMS Full data from both studies will be shared at ...

Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo ...

It has been 10 years since J.P. Morgan launched its annual e-Trading Edit, a comprehensive survey of trends and topics in the ...

The safety profile of atacicept across the ORIGIN program appears favorable, and comparable to placebo Biologics License Application (BLA) submission through the Accelerated Approval Program to the U.

"Public and private markets are converging, but the data infrastructure hasn't kept pace," said Nicholas Fusco, CEO of PM Insights. "We're not just aggregating data; we're revealing the economic ...